Government/Regulatory, Industry News

Industry cites outdated standards as flaw in FDA’s real-world data draft guidance

Posted 11 February 2022 | By Joanne S. Eglovitch  The US Food and Drug Administration (FDA) should adopt updated data standards that accommodate the “evolving and emerging” nature of real-world data not currently reflected in the Data Standards Catalogue, according to industry comments on the agency’s draft guidance. Overall, comments from…

Clinical Trials, Competitor News

Radicle Science Makes History Again With First Large-Scale Clinical Trials on Rare Cannabinoids, Including THCV, CBN, CBG, and CBC

Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021. February 10, 2022 06:00 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Radicle Science, a transformative healthtech B-corp validating health and…

Collaborations, Partner and Collaborator News

Palantir Technologies Extends Partnership with Ferrari to Bring Data Driven Performance Decisions to Race Operations

February 10, 2022 05:45 AM Eastern Standard Time DENVER–(BUSINESS WIRE)–Palantir Technologies Inc. (“Palantir,” NYSE:PLTR), a leading builder of operating systems for the modern enterprise, today announced a new one year extended partnership with Ferrari to bring its world class data and analytics technology to Scuderia Ferrari. In addition to Scuderia…

Collaborations, Competitor News, Oncology, Pharma

Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs

February 09, 2022 06:55 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO® and other therapies in Loxo Oncology at Lilly’s pipeline. The partnership will initially explore…

Competitor News, M&A, Oncology

Tempus Announces the Acquisition of Highline Sciences

Tempus Announces the Acquisition of Highline Sciences February 08, 2022 08:00 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced the acquisition of Highline Sciences, a ​​specialized, full-service clinical contract research organization (CRO) focused on oncology. “Joining forces with Tempus creates a unique…

Collaborations, Competitor News, COVID-19

Vault Health Partners with Datavant to Enable Connectivity to Millions of COVID-19 Test Results and Unlock Pandemic Insights

SAN FRANCISCO, Feb. 8, 2022 /PRNewswire/ — Vault Health, a national leader in remote diagnostics and COVID testing, and Datavant, the leader in helping organizations securely de-identify and connect health data, today announced a collaboration to enable life sciences and healthcare organizations to connect their data to Vault’s vast set of COVID-19 test…

Collaborations, Competitor News, Data Partnership

New Benchmark Report from NIST, Baylor College of Medicine and DNAnexus Helps Provide Accurate Identification of Variants in Challenging Medically Relevant Genes

New Nature Biotechnology publication advances efforts to improve genome sequencing information for diagnosis and treatment of diseaseFebruary 08, 2022 08:03 AM Eastern Standard Time MOUNTAIN VIEW, Calif. & HOUSTON–(BUSINESS WIRE)–Researchers from National Institute of Standards and Technology (NIST), Baylor College of Medicine and DNAnexus, Inc., together with other members of the Genome in a Bottle (GIAB) consortium,…